• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today

    6/29/23 9:01:57 PM ET
    $AUPH
    $GS
    $NKE
    $SGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AUPH alert in real time by email

    U.S. stocks traded mixed at the closing bell today, with the Dow Jones Industrial Average gaining more than 250 points, up 0.8% to 34,122.42 The NASDAQ, however, was unchanged at 13,591.33, while the S&P 500 rose 0.45% to 4,396.44.

    These are the top stocks that gained the attention of retail traders and investors throughout the day:

    Aurinia Pharmaceuticals Inc.

    (NASDAQ:AUPH)

    Aurinia Pharmaceuticals Inc. stock closed 0.22% lower on Wednesday at $9.16. The stock had an intraday high of $9.31 and an intraday low of $9.11. In the wider picture, the stock has a 52-week high of $12.6 and a 52-week low of $4.07. The company announced that its Board of Directors has initiated an exploration of strategic alternatives, including a potential sale, merger, or other strategic transaction.

    Nike Inc.

    (NYSE:NKE)

    Nike Inc. stock closed 0.28% higher on Wednesday at $113.37. The stock had an intraday high of $114.27 and an intraday low of $112.61. In the wider picture, the stock has a 52-week high of $131.31 and a 52-week low of $82.22. The company reported fourth-quarter revenue of $12.82 billion, up 10% year-over-year, beating the Street consensus estimate.

    Tesla Inc.

    (NASDAQ:TSLA)

    Tesla Inc. stock closed 0.49% higher on Wednesday at $257.5. The stock had an intraday high of $260.74 and an intraday low of $253.61. In the wider picture, the stock has a 52-week high of $314.67 and a 52-week low of $101.81. Reports indicate that Tesla may have achieved a strong second quarter in Australia, with fewer than 20 vehicles remaining available for purchase nationwide.

    The Goldman Sachs Group Inc.

    (NYSE:GS)

    The Goldman Sachs Group Inc. stock closed 3.01% higher on Wednesday at $323.09. The stock had an intraday high of $325.5 and an intraday low of $316.25. In the wider picture, the stock has a 52-week high of $389.58 and a 52-week low of $277.84. Bank stocks rose Thursday as multiple U.S. institutions cleared the Federal Reserve’s stress tests a day prior.

    Sigilon Therapeutics Inc.

    (NASDAQ:SGTX)

    Sigilon Therapeutics Inc. stock closed 440.92% higher on Wednesday at $21.15. The stock had an intraday high of $28 and an intraday low of $20.58. In the wider picture, the stock has a 52-week high of $28 and a 52-week low of $3.77. The company’s shares skyrocketed after Eli Lilly And Co agreed to acquire the company for a purchase price of $14.92 per share in cash.

    Stay on top of things with your trading when the premarket session opens.

    Benzinga Newsbot

    Hi, I am the Benzinga Newsbot! I wrote the above article, utilizing the sources I hyperlinked above. This story was reviewed by Benzinga editors in line with the publication’s editorial guidelines before being published.

    Get the next $AUPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUPH
    $GS
    $NKE
    $SGTX

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    Tesla Inc.
    $TSLA
    1/2/2026$444.00 → $439.00Hold
    Truist
    Nike Inc.
    $NKE
    12/19/2025$75.00 → $72.00Market Perform
    Telsey Advisory Group
    Nike Inc.
    $NKE
    12/19/2025$78.00 → $68.00Buy
    Needham
    More analyst ratings

    $AUPH
    $GS
    $NKE
    $SGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Analyst reiterated coverage on Tesla with a new price target

    Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously

    1/30/26 8:00:23 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Wells Fargo reiterated coverage on Tesla with a new price target

    Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $130.00 from $120.00 previously

    1/12/26 9:31:17 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $AUPH
    $GS
    $NKE
    $SGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LUPKYNIS

    Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

    1/25/21 11:31:10 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    $GS
    $NKE
    $SGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hut 8 Reports Fourth Quarter and Full Year 2025 Results

    Power-first model delivers first AI infrastructure transaction and advances multi-gigawatt growth strategy8,500 MW1 development pipeline as of December 31, 2025 sets foundation for scalable, repeatable execution in 2026Earnings Release HighlightsCommercialized AI infrastructure at scale, signing a 15-year, 245 MW IT lease with Fluidstack at the River Bend campus, representing $7.0 billion in base-term contract value.Refined portfolio structure and streamlined capital allocation framework through the sale of a 310 MW portfolio of four natural gas-fired power plants, which closed in February 2026, and the launch and public listing of American Bitcoin Corp., a majority-owned Bitcoin accumulatio

    2/25/26 6:30:00 AM ET
    $GS
    $HUT
    $JPM
    Investment Bankers/Brokers/Service
    Finance
    Finance: Consumer Services
    Major Banks

    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com

    2/19/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $AUPH
    $GS
    $NKE
    $SGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 32,901 shares, decreasing direct ownership by 5% to 662,900 units (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    2/23/26 4:08:05 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Greenleaf Peter covered exercise/tax liability with 100,171 shares, decreasing direct ownership by 5% to 1,744,866 units (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    2/23/26 4:07:03 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Miller Joseph M covered exercise/tax liability with 32,424 shares, decreasing direct ownership by 6% to 556,703 units (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    2/23/26 4:05:56 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    $GS
    $NKE
    $SGTX
    SEC Filings

    View All

    SEC Form 10-K filed by Goldman Sachs Group Inc.

    10-K - GOLDMAN SACHS GROUP INC (0000886982) (Filer)

    2/25/26 5:22:27 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form FWP filed by Goldman Sachs Group Inc.

    FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

    2/25/26 5:05:02 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 144 filed by Tesla Inc.

    144 - Tesla, Inc. (0001318605) (Subject)

    2/25/26 4:27:12 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $AUPH
    $GS
    $NKE
    $SGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Swan Robert Holmes bought $500,080 worth of Class B Common Stock (8,691 units at $57.54), increasing direct ownership by 25% to 43,293 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:21:15 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $AUPH
    $GS
    $NKE
    $SGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Lambda Appoints Stacey Finerman as VP, Investor Relations

    Seasoned IR Leader from Zayo Group, Marqeta, and Square Brings Deep Expertise Lambda, the Superintelligence Cloud, today announced the appointment of Stacey Finerman as VP, Investor Relations. Finerman brings over a decade of experience in financial communications and capital markets strategy to support Lambda's next stage of growth as a leader in AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021703561/en/Stacey Finerman, VP, Investor Relations "We're delighted to have Stacey join our team. Stacey's significant experience strengthens our investor relations capabilities and adds a new set of relationships

    10/21/25 8:00:00 AM ET
    $C
    $EB
    $GS
    Major Banks
    Finance
    Computer Software: Programming Data Processing
    Technology

    Divcon Controls Names Marc Shiffman CEO

    With two decades of experience managing companies to exceptional results, Shiffman is well qualified to lead Divcon through a rapid phase of growth Divcon Controls ("Divcon"), a global systems integrator delivering facility management automation and monitoring solutions to the world's biggest mission-critical data center operators, announced today that Marc Shiffman has become its new Chief Executive Officer and has joined the company's Board of Directors. Mr. Shiffman joins Divcon with extensive experience in technology and services leadership, having successfully run multiple companies as an operationally adept executive in partnership with innovative founders. Most recently, Mr. Shif

    10/14/25 7:04:00 AM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    $AUPH
    $GS
    $NKE
    $SGTX
    Financials

    Live finance-specific insights

    View All

    Hut 8 Reports Fourth Quarter and Full Year 2025 Results

    Power-first model delivers first AI infrastructure transaction and advances multi-gigawatt growth strategy8,500 MW1 development pipeline as of December 31, 2025 sets foundation for scalable, repeatable execution in 2026Earnings Release HighlightsCommercialized AI infrastructure at scale, signing a 15-year, 245 MW IT lease with Fluidstack at the River Bend campus, representing $7.0 billion in base-term contract value.Refined portfolio structure and streamlined capital allocation framework through the sale of a 310 MW portfolio of four natural gas-fired power plants, which closed in February 2026, and the launch and public listing of American Bitcoin Corp., a majority-owned Bitcoin accumulatio

    2/25/26 6:30:00 AM ET
    $GS
    $HUT
    $JPM
    Investment Bankers/Brokers/Service
    Finance
    Finance: Consumer Services
    Major Banks

    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com

    2/19/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $AUPH
    $GS
    $NKE
    $SGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

    SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    11/14/24 4:47:34 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Goldman Sachs Group Inc.

    SC 13G/A - GOLDMAN SACHS GROUP INC (0000886982) (Filed by)

    11/8/24 5:34:28 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Goldman Sachs Group Inc.

    SC 13G/A - GOLDMAN SACHS GROUP INC (0000886982) (Filed by)

    11/5/24 6:23:11 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance